Florida Cancer Specialists & Research Institute (FCS) has partnered with Paradigm Health to expand patient access to clinical trials using Paradigm's technology platform.

The partnership aims to streamline clinical trial planning, recruitment, and execution across FCS' 33 research locations. Paradigm's AI-enabled platform will allow FCS to screen all patients for trial eligibility, potentially increasing participation in innovative cancer treatments. The collaboration is expected to benefit patients by providing more opportunities to access cutting-edge therapies closer to home.

FCS, which treats over 600 patients annually in clinical trials as of September 2024, sees this partnership as a way to expand its early- and late-phase clinical trial capabilities. Integrating Paradigm's technology is anticipated to reduce administrative burdens, accelerate patient-trial matching, and strengthen FCS's ability to reach traditionally underserved communities.

Analyst QuickTake : This marks the second partnership Paradigm has established in 2024. In August , Paradigm partnered with Fujitsu to improve clinical trials and address drug loss in Japan. The partnership aimed to streamline medical institution data collection and processing, accelerate clinical trial planning, and attract global trials to Japan. With its collaboration with FCS, the company appears to be increasing its market presence further across the US.